◦ I believe Cytodyn price is being manipulated by
◦ I believe Cytodyn price is being manipulated by forces related to big Pharma. Think Merck or Gilead. It’s easy for four or five or more traders related to big Pharma to trade between themselves and maintain a low price. This has been going on for years with other companies.
◦ Pharma obviously knows the low stock price hurts the company’s ability to raise money and gives them an advantage in partnership negotiations that are, right now, going on. Big pharma knows, as we do, that the data is exciting, with more coming this month. Their advantage ends with the FDA granting breakthrough or accelerated approval recently applied for by Doc Jay. Furthermore I think a a partnership deal is near completion and only waits on the FDA. My guess…Merck.
Doctor Jay Lalezari is a humanitarian, a brilliant researcher, and a highly articulate leader. Robert Hoffman, our financial leader with years of experience with big Pharma, came out of retirement for this great chance to change the world of cancer treatment.
Hang in there, after years of waiting what’s a few more months.
14
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding Centrus Energy's Short Interest Trends Centrus Energy (NYSE: LEU) has recently experienced a notable rise in short interest, reporting that 2.01 million of its shares are currently sold short. This figure accounts for approximately 12.93% of all regularly available shares for trading. A key point to note is that the percentage of float sold short has surged...
Continue Reading
Blink Charging Initiatives to Transform EV Infrastructure Blink Charging Co. (NASDAQ: BLNK) is actively working toward enhancing its presence in the electric vehicle (EV) charging domain through innovative initiatives and strategic partnerships. Collaborating with Karbon Homes for Sustainable Living In an exciting development, Blink has formed a partnership with Karbon...
Continue Reading
Financial Performance Overview Butler National Corporation showcased remarkable financial performance in the second quarter of fiscal year 2025. Operating income surged by 35%, reaching $4.9 million compared to $3.6 million in the same quarter of the previous year. This increase is a reflection of the company’s robust strategies in the aircraft modification and gaming...
Continue Reading
AI's Impact on Job Opportunities It's quite striking how artificial intelligence (AI) is reshaping job landscapes, particularly for computer science graduates. A notable article recently highlighted the distressing trend of diminishing job prospects for young talent in the face of rapid AI advancements. The research, conducted by professors from a prestigious university,...
Continue Reading
Nebius Group’s Revenue Growth Amidst Financial Losses Nebius Group N.V. (NASDAQ: NBIS) recently encountered a challenging market, with shares experiencing a notable drop. They reached a low of $38.50 before making a recovery to surpass $48. This fluctuation has drawn attention as investors process the company's latest financial statements. Impressive Financial Results...
Continue Reading